Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN63,7463,980,88
Msft2,15
Nokia4,14254,185,37
IBM0,41
Daimler AG37,72537,7453,14
PFE0,00
07.07.2020 8:00:15
Indexy online
AD Index online
select
AD Index online
 

  • 06.07.2020
IDEXX Labs (IDXX.O, NASDAQ Cons)
Závěr k 6.7.2020 Změna (%) Změna (USD) Objem obchodů (ks)
339,47 1,41 4,71 401 804
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 07.07.2020
Popis společnosti
Obecné informace
Název společnostiIDEXX Laboratories, Inc.
TickerIDXX
Kmenové akcie:Ordinary Shares
RICIDXX.O
ISINUS45168D1046
Poslední známé roční výsledky31.12.2019
Poslední známé čtvrtletní výsledky31.03.2020
Počet zaměstnanců k 07.02.2020 9 200
Akcie v oběhu k 27.04.2020 84 932 969
Počet akcionářů k 31.12.2019 420
MěnaUSD
Konstituent indexůS&P 500
Kontaktní informace
Ulice1 Idexx Dr
MěstoWESTBROOK
PSČ04092-2041
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon12 075 560 300
Fax12075564346

Business Summary: IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include diagnostic and information technology-based products and services for the veterinary market, which the Company refers to as the Companion Animal Group; water quality products; diagnostic products and services for livestock and poultry health, which the Company refers to as Livestock, Poultry and Dairy, and Other operating segment, which combines and presents products for the human point-of-care medical diagnostics market with its pharmaceutical product line and its out-licensing arrangements. Its products and services include point-of-care veterinary diagnostic products, comprising instruments, consumables and rapid assay test kits, among others.
Financial Summary: BRIEF: For the three months ended 31 March 2020, IDEXX Laboratories, Inc. revenues increased 9% to $626.3M. Net income increased 9% to $111.8M. Revenues reflect CAG segment increase of 8% to $552M, Water segment increase of 13% to $34.1M, LPD segment increase of 8% to $34.2M, United States segment increase of 11% to $396.8M, Europe & Middle East & Africa (EMEA) (Region) segment increase of 7% to $129.8M, Asia Pacific segment increase of 6% to $63.5M.
Odvětvová klasifikace
TRBC2012Veterinary Medical Equipment & Supplies
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYFish/Livestock
MGSECTORConsumer/Non-Cyclical
NAICSVeterinary Services
NAICSAnalytical Laboratory Instrument Manufacturing
NAICSCustom Computer Programming Services
NAICSInVitro Diagnostic Substance Manufacturing
SICDiagnostic Substances
SICVeterinary Services, Specialties
SICAnalytical Instruments
SICComputer Programming Services
SICDiagnostic Substances



  • Poslední aktualizace: 07.07.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the BoardLawrence Kingsley5701.11.201901.11.2019
President, Chief Executive Officer, DirectorJonathan Mazelsky5923.10.2019
Chief Financial Officer, Executive Vice President, TreasurerBrian McKeon5701.01.201401.01.2014
Chief Human Resource Officer, Corporate Vice PresidentGiovani Twigge56
Executive Vice President, General Manager, Point of Care Diagnostics and Worldwide OperationsTina Hunt52
Executive Vice President, General Manager, Reference Laboratories and Information TechnologyMichael Lane52
Executive Vice President and Chief Commercial OfficerJames Polewaczyk5705.02.2007
Corporate Vice President and Chief Marketing OfficerKathy Turner56
Corporate Vice President, General Counsel, and Corporate SecretarySharon Underberg5801.03.201901.03.2019